1. Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine EUA letter of authorization reissued July 8, 2022. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2022. https://www.fda.gov/media/150386/download
2. Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine EUA letter of authorization reissued June 17, 2022. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2022. https://www.fda.gov/media/144636/download
3. Food and Drug Administration, Vaccines and Related Biological Products Advisory Committee. FDA briefing document: EUA amendment request for Pfizer-BioNTech COVID-19 vaccine for use in children 6 months through 4 years of age. Vaccines and Related Biological Products Advisory Committee meeting; June 15, 2022; Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2022. https://www.fda.gov/media/159195/download
4. Food and Drug Administration, Vaccines and Related Biological Products Advisory Committee. FDA briefing document: EUA amendment request for use of the Moderna COVID-19 vaccine in children 6 months through 17 years of age. Vaccines and Related Biological Products Advisory Committee meeting; June 14–15, 2022; Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2022. https://www.fda.gov/media/159189/download
5. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).;Shimabukuro;Vaccine,2015